Rachel Orbuch,Amanda Cheung
Rachel Orbuch
Cirrhosis recompensation: what it is and what it ought to be - insights from the philosophy of science [0.03%]
肝硬化复发：什么是以及应该是什么——科学哲学的视角
Mario Romero-Cristobal
Mario Romero-Cristobal
Lorenzo Ridola,Oliviero Riggio
Lorenzo Ridola
From the Editor's Desk. [0.03%]
编者来信
Philip Newsome,Frank Tacke,Heiner Wedemeyer et al.
Philip Newsome et al.
Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acutely decompensated cirrhosis [0.03%]
RIPK3作为预测失代偿期肝硬化患者结局的新型生物标志物的鉴定与验证
Nipun Verma,Pratibha Garg,Parminder Kaur et al.
Nipun Verma et al.
Background: In cirrhosis patients with acute decompensation (AD) and acute-on-chronic liver failure (ACLF) non-apoptotic forms of cell death predominate with increasing severity, which are potential targets of therapy. Th...
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma [0.03%]
ADP-A2AFP TCR-T细胞治疗晚期肝细胞癌或胃黏液样癌I期临床试验
Tim Meyer,Richard S Finn,Mitesh Borad et al.
Tim Meyer et al.
Background & aims: Patients with advanced hepatocellular carcinoma (HCC) generally experience poor outcomes despite current therapies; alternative treatments are needed. ADP-A2AFP is an investigational autologous T-cell t...